- •
Recurrent respiratory papillomatosis (RRP) is a devastating, albeit rare, disease in which papillomas of the airway cause hoarseness and airway obstruction.
- •
Surgical therapy for RRP requires a team approach with otolaryngologists, anesthesia providers, and operating room personnel working together in a facility properly equipped to manage difficult airways.
- •
The recent introduction of a 9-valent human papillomavirus vaccine offers hope for prevention of transmission of the virus to neonates and
Update on Recurrent Respiratory Papillomatosis
Section snippets
Key points
Natural history and risk factors
RRP is a heterogeneous disease, caused by 2 primary strains of HPV (HPV 6 and HPV 11), and presenting in 2 predominant age groups (juvenile onset, occurring before the age of 12 years; and adult onset, occurring from 20–40 years of age). It has previously been shown that HPV 11 is the more aggressive viral strain of the two, and that younger age of presentation is associated with a more detrimental course.3
Recent work has brought an understanding of the natural history of adult-onset RRP
Frontiers in medical treatment
Until HPV vaccination rates reach levels high enough to promote herd immunity, RRP will still demand further advances in treatment. Although surgical treatment continues to be vital in both the diagnosis as well as control of the disease, major strides are being made in the basic sciences that may pave the way to further medical therapies. These advances range from novel DNA vaccine development to the investigational use of therapies previously used to treat viral hepatitis or ocular neoplastic
Summary
RRP is a frustrating, capricious disease with the potential for morbid consequences because of its involvement of the airway and the risk of malignant degeneration. The goals of surgical therapy are to maintain a safe airway with a serviceable voice while avoiding excessive scarring. When children require surgical therapy more frequently than 4 times in 12 months or have evidence of distal spread of RRP outside of the larynx, adjuvant medical therapy should be considered.
Universal or
References (53)
- et al.
Perinatal transmission of human papillomavirus from gravidas with latent infections
Obstet Gynecol
(1999) - et al.
Prophylactic quadrivalent HPV (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo controlled multi-centre phase II efficacy trial
Lancet Oncol
(2005) - et al.
The use of the quadrivalent human papillomavirus vaccine (Gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma
J Voice
(2015) - et al.
Therapeutic use of the HPV vaccine in recurrent respiratory papillomatosis: a case report
Int J Pediatr Otorhinolaryngol
(2017) - et al.
Gardasil vaccination for recurrent laryngeal papillomatosis in adult men: first report: changes in HPV antibody titer
J Voice
(2017) - et al.
Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature
Chest
(2000) Cidofovir for recurrent respiratory papillomatosis (RRP): a re-assessment of risks
Int J Pediatr Otorhinolaryngol
(2005)- et al.
Voice outcomes following repeated surgical resection of laryngeal papillomata in children
Otolaryngol Head Neck Surg
(2009) - et al.
The cost of juvenile-onset recurrent respiratory papillomatosis
Arch Otolaryngol Head Neck Surg
(2000) - et al.
Quality of life of patients with recurrent respiratory papillomatosis
Laryngoscope
(2017)
Recurrent respiratory papillomatosis: update 2008
Curr Opin Otolaryngol Head Neck Surg
Laryngeal distribution of recurrent respiratory papillomatosis in a previously untreated cohort
Laryngoscope
Laryngopharyngeal reflux and herpes simplex virus type 2 are possible risk factors for adult-onset recurrent respiratory papillomatosis (prospective case-control study)
Clin Otolaryngol
Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx
Proc Natl Acad Sci U S A
Recurrent respiratory papillomatosis in children: a retrospective study of management and complications
Ear Nose Throat J
Use of the pediatric quality of life inventory to assess the health-related quality of life in children with recurrent respiratory papillomatosis
Ann Otol Rhinol Laryngol
Task force on recurrent respiratory papillomas. A preliminary report
Arch Otolaryngol Head Neck Surg
National registry for juvenile-onset recurrent respiratory papillomatosis
Arch Otolaryngol Head Neck Surg
Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle
Clin Infect Dis
A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a National HPV Vaccination Program
J Infect Dis
Quadrivalent vaccine against HPV to prevent high-grade cervical lesions
N Engl J Med
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
N Engl J Med
Quadrivalent HPV: recommendations of the ACIP
Recommendations on the use of quadrivalent human papillomavirus vaccine in males—Advisory Committee on Immunization Practices (ACIP)
Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women
JAMA
National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2016
MMWR Morb Mortal Wkly Rep
Cited by (0)
Disclosure: The authors have nothing to disclose.